BHC

6.08

1.30% -0.08

Dopo l'orario di chiusura: 6.15 0.07 +1.15%

Bausch Health Companies Inc (BHC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BHC Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$6.16

Aprire:

$6.11

Volume 24 ore:

2.55M

Relative Volume:

1.03

Capitalizzazione di mercato:

$2.25B

Reddito:

$9.47B

Utile/perdita netta:

$-178.00M

Rapporto P/E:

-12.67

EPS:

-0.48

Flusso di cassa netto:

$1.01B

1 W Prestazione:

+7.42%

1M Prestazione:

-17.95%

6M Prestazione:

-8.71%

1 anno Prestazione:

-4.55%

Intervallo 1D:

$5.97

$6.20

Intervallo di 1 settimana:

$5.62

$6.305

Portata 52W:

$4.25

$8.685

Bausch Health Companies Inc Stock (BHC) Company Profile

Nome

Bausch Health Companies Inc

Settore

Healthcare (1108)

Industria

Drug Manufacturers - Specialty & Generic (83)

Telefono

514-744-6792

Indirizzo

2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC

Dipendente

20,700

Cinguettio

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

BHC's Discussions on Twitter

Compare BHC vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BHC Bausch Health Companies Inc	6.08	2.28B	9.47B	-178.00M	1.01B	-0.48
TAK Takeda Pharmaceutical Co Adr	18.28	57.18B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	128.67	56.47B	9.40B	2.65B	2.24B	5.935
HLN Haleon Plc Adr	11.16	49.16B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	34.31	40.03B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	475.85	20.37B	3.13B	1.27B	1.12B	26.39

Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-09	Iniziato	Barclays	Equal Weight
2024-08-02	Downgrade	Piper Sandler	Neutral → Underweight
2024-07-10	Iniziato	Raymond James	Mkt Perform
2023-09-20	Aggiornamento	Jefferies	Hold → Buy
2023-06-16	Downgrade	TD Cowen	Outperform → Market Perform
2022-07-29	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2022-07-29	Downgrade	Truist	Buy → Hold
2022-07-28	Downgrade	JP Morgan	Overweight → Neutral
2022-06-13	Ripresa	JP Morgan	Overweight
2021-03-24	Downgrade	BofA Securities	Neutral → Underperform
2021-02-17	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2021-01-22	Downgrade	Piper Sandler	Overweight → Neutral
2020-09-17	Aggiornamento	BofA Securities	Underperform → Neutral
2020-08-24	Reiterato	H.C. Wainwright	Buy
2020-06-17	Reiterato	H.C. Wainwright	Buy
2020-04-24	Iniziato	Citigroup	Buy
2020-04-02	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-01-29	Downgrade	Wolfe Research	Outperform → Peer Perform
2020-01-22	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2019-12-12	Aggiornamento	JP Morgan	Neutral → Overweight
2019-12-02	Iniziato	Goldman	Neutral
2019-10-25	Iniziato	Cowen	Outperform
2019-09-12	Iniziato	Guggenheim	Buy
2019-08-15	Aggiornamento	TD Securities	Hold → Buy
2019-07-19	Iniziato	Wolfe Research	Outperform
2019-06-11	Ripresa	Barclays	Overweight
2019-05-13	Aggiornamento	JP Morgan	Underweight → Neutral
2019-03-20	Iniziato	SunTrust	Buy
2019-01-02	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-11-05	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-09-13	Aggiornamento	Piper Jaffray	Underweight → Neutral

Mostra tutto

Bausch Health Companies Inc Borsa (BHC) Ultime notizie

Feb 11, 2026

Idahoans may be eligible for money from generic drug settlement - KMVT

Feb 11, 2026

Idaho joins $17.85M settlement over alleged generic drug price-fixing - KTVB

Feb 11, 2026

$17.85 Million in Settlements in Ongoing Generic Drug Price-Fixing Conspiracy Cases - Big Country News

Feb 11, 2026

Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth - Finviz

Feb 11, 2026

Is Bausch Health (BHC) Pricing Reflect Long Term Potential After 81% Five Year Share Slump - Sahm

Feb 08, 2026

Feb 07, 2026

Migraine Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | GSK, Merck, Pfizer, Bausch Health, Amgen, Abbvie AstraZeneca, Eli Lilly and Co - Barchart.com

Feb 07, 2026

The Truth About Bausch Health Companies: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS

Feb 07, 2026

Lupin’s Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch HealthLupin | Press Release - lupin.com

Feb 07, 2026

AG Drummond reaches settlement with drug companies accused of price-fixing - fox23.com

Feb 07, 2026

The Bull Case For Bausch Health Companies (BHC) Could Change Following Failed Xifaxan RED-C Trials Learn Why - Yahoo Finance

Feb 07, 2026

Wall Street Zen Upgrades Bausch Health Cos (NYSE:BHC) to "Strong-Buy" - MarketBeat

Feb 07, 2026

Feb 06, 2026

Are you eligible to receive a portion of $17 million pharmaceutical settlement? - FourStatesHomepage.com

Feb 06, 2026

Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results - Finviz

Feb 06, 2026

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Qiagen (QGEN) and InnovAge Holding (INNV) - The Globe and Mail

Feb 06, 2026

Feb 05, 2026

CT Prescription Buyers Could See Refunds In $17.9M Drug Price-Fixing Settlement - AOL.com

Feb 05, 2026

Quarterly Earnings: Is HGBL in a long term uptrendTrade Risk Summary & Real-Time Market Trend Scan - baoquankhu1.vn

Feb 05, 2026

Feb 04, 2026

Connecticut AG William Tong settles with Lannett and Bausch for nearly $18 million - fox61.com

Feb 04, 2026

Michigan AG Secures $17.85M in Settlements with Lannett, Bausch Over Generic Drug Price-Fixing Allegations - Hoodline

Feb 04, 2026

Nebraska Attorney General’s Office Announces Settlements with Lannett and Bausch Totaling $17.85 Million Over Conspiracies to Inflate Prices and Limit Competition - chadronradio.com

Feb 04, 2026

Maryland Announces $17.85 Million Settlement in Drug Pricing Case - The MoCo Show -

Feb 04, 2026

Maryland Attorney General announces $17.85 million settlements with generic drug manufacturers - nottinghammd.com

Feb 04, 2026

Feb 03, 2026

Analyst Downgrade: Is now the right time to enter ADNT2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn

Feb 03, 2026

Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention - Finviz

Feb 03, 2026